What does CUSIP 74365A309 represent in this 13F holders report?

CUSIP 74365A309 is the security identifier for PLX - Protalix BioTherapeutics, Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held PLX - Protalix BioTherapeutics, Inc. - Common Stock in Q3 2025?

76 institutional investors reported PLX - Protalix BioTherapeutics, Inc. - Common Stock for Q3 2025. Use the holders table for investor-level position and value details.

Protalix BioTherapeutics, Inc. - Common Stock (PLX)

CUSIP: 74365A309

Q3 2025 13F Holders as of 30 Sep 2025

Security type / class: Equity / Common Stock
Total 13F shares: 13,927,352
Total 13F value: $30,914,125
Share change: +2,010,323
Put/Call ratio: 400%
SEC-reported price per share: $2.22
Number of holders: 76
Value change: +$4,618,112
Number of buys: 32
Number of sells: 24
Shares outstanding: 80,610,558

Security key

74365A309

Report period

Q3 2025

Institutions

Top holders

PLX full security history Ownership snapshot Full 13F holder table Protalix BioTherapeutics, Inc. SEC filings Protalix BioTherapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of PLX - Protalix BioTherapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Gilad Mamlok

Disclosed value leader

BlackRock, Inc.

Comparable rows

15/15

Latest evidence

24 Aug 2025

3/4/5 13F Lead comparable stake: 0% Showing 1-6 of 15 holder rows.

Quick read

Gilad Mamlok leads the comparable SEC ownership view at 0%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Gilad Mamlok's linked filing trail.

Comparable ownership Top 5

Gilad Mamlok 0%

BlackRock, Inc. 4.2%

RENAISSANCE TECHNOLOGIES LLC 2%

NORTHERN TRUST CORP 1.3%

GEODE CAPITAL MANAGEMENT, LLC 1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Gilad Mamlok	3/4/5 Sr. VP and CFO 3/4/5	0%	$7,770 3,631 shares	—	24 Aug 2025
BlackRock, Inc.	13F Company 13F	4.2%	$4,987,113 3,369,670 shares	—	30 Jun 2025
RENAISSANCE TECHNOLOGIES LLC	13F Company 13F	2%	$2,390,204 1,615,003 shares	—	30 Jun 2025
NORTHERN TRUST CORP	13F Company 13F	1.3%	$1,597,990 1,079,723 shares	—	30 Jun 2025
GEODE CAPITAL MANAGEMENT, LLC	13F Company 13F	1%	$1,222,972 826,333 shares	—	30 Jun 2025
Connor, Clark & Lunn Investment Management Ltd.	13F Company 13F	0.62%	$734,400 496,216 shares	—	30 Jun 2025

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

13,927,352

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2025 vs Q2 2025 Across Filers

Q2 2025 holders

Q3 2025 holders

Holder diff

Investor	Q2 2025 Shares	Q3 2025 Shares	Share Diff	Share Chg %	Q2 2025 value	Q3 2025 value	Value change	Value Chg %